Surgical Treatment of Sinus Disease

Description of Procedure or Service

Chronic sinusitis is one of the most frequently diagnosed chronic medical conditions. Chronic sinusitis is characterized by nasal discharge, usually without fever, that persists for more than 12 weeks. Symptoms of congestion often accompany the nasal discharge. There also may be mild pain and/or headache. Thickening of mucosa may restrict or close natural openings between sinus cavities and the nasal fossae. Considerable variation exists in the location and shape of these sinus ostia. A course of conservative medical therapy is attempted initially to resolve the symptoms; this treatment may include antibiotics, nasal irrigation, decongestants, and steroids.

In some cases of chronic sinusitis, surgical drainage may be necessary. Functional endoscopic sinus surgery (FESS) is the most commonly used surgical technique to treat medically unresponsive chronic sinusitis and other serious conditions of the nasal sinuses that result in impaired sinus drainage. It involves the removal of varying amounts of tissue and the opening of sinus ostia to treat chronic sinusitis. The use of the endoscope permits a better view of the surgical field. Goals of FESS are to allow for maximum preservation of mucosa, and to open and enlarge the sinus passageways allowing for proper drainage and optimizing access for topical medications.

FESS is performed using a rigid endoscope to view the structures of the nose and sinuses. The endoscope is inserted through the nose, as are the surgical instruments the surgeon uses to perform the surgery. The procedure can be performed under general or local anesthesia on an outpatient basis, and patients usually experience minimal discomfort. The use of FESS allows for a much less invasive and traumatic procedure than open or non-endoscopic sinus surgery. There are shorter surgery and healing times, less postoperative discomfort, and fewer surgical complications with FESS. However, because of the proximity of sinus structures to the eyes and the brain, it is not risk free.

Some form of sinus packing is generally utilized postoperatively. Simple dressings, both absorbable and non-absorbable, can be inserted following surgery. These can serve as both hemostatic agents and/or middle meatal spacers. There is some RCT evidence that middle meatal spacers may reduce the formation of synechiae following FESS, although the available studies have significant heterogeneity in this outcome.

Implantable drug-eluting sinus implants are another option for postoperative management following FESS and other sinus procedures. These implants are inserted under endoscopic guidance to stabilize the sinus openings and the turbinates, reduce edema, and/or prevent obstruction by adhesions. They also deliver medications (e.g. steroids) topically over an extended period of time (e.g. 30 days), and this local delivery of medications may be superior to other treatment options in the postoperative setting.

In 2011, the PROPEL® system (Intersect ENT, Palo Alto, CA) was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process. This device is a self-expanding, bioabsorbable, steroid-eluting stent intended for use in the ethmoid sinus. It is placed via endoscopic guidance using an applicator included with the device. Steroids (mometasone furoate) are embedded in a polyethylene glycol polymer, which allows sustained release of the drug over an approximate duration of 30 days. The device dissolves over several weeks, and therefore does not require removal. In 2012, a smaller version of the PROPEL® device, the PROPEL® mini Sinus Implant, was approved.
Surgical Treatment of Sinus Disease

for use in patients older than age 18 years following ethmoid sinus surgery to maintain patency and later expanded to the frontal sinus following frontal sinus surgery in 2016. In 2017, the PROPEL® Contour was approved through a premarket approval supplement. The PROPEL® Contour sinus implant is an adaptable implant that is designed to maximize drug delivery to the frontal and maxillary sinus.

In December 2017, the U.S. Food and Drug Administration (FDA) approved Sinuva (mometasone furoate) Sinus Implant for the treatment of nasal polyps in patients 18 years of age or older who have had ethmoid sinus surgery.

There are numerous other stenting and packing materials commonly used in sinus surgery. This policy does not apply to the use of those materials.

Related Policies:
Maximum Units of Service

***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician.

Policy

BCBSNC will cover surgical treatment of sinus disease when it is determined to be medically necessary because the medical criteria and guidelines shown below are met.

Benefits Application

This medical policy relates only to the services or supplies described herein. Please refer to the Member’s Benefit Booklet for availability of benefits. Member’s benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy.

When surgical treatment of sinus disease is covered

Functional endoscopic sinus surgery (FESS) is considered medically necessary for the treatment of sinusitis, polyposis, sinus tumor, or other conditions listed below when any one or more of the following circumstances is present:

1. Uncomplicated sinusitis and all of the following:
   a. Either four or more documented episodes of acute rhinosinusitis in one year, or chronic sinusitis that interferes with lifestyle; and,
   b. Optimal medical therapy has been attempted and failed; and,
   c. For chronic rhinosinusitis, documentation of coronal CT and/or nasal endoscopy following optimal medical therapy showing persistent sinus pathology; and,
   d. For recurrent acute rhinosinusitis, coronal CT and nasal endoscopy may be normal after treatment. However, CT and/or nasal endoscopy during acute rhinosinusitis should document sinus pathology amenable to surgical treatment.

2. Multiple or recurrent polyps with symptoms and failure of optimal medical management (including assessment for allergy symptoms and allergy evaluation if indicated) with persistent sinus disease on follow up CT scan and/or nasal endoscopy,

3. Complications of sinusitis, including extension to adjacent structures,
Surgical Treatment of Sinus Disease

4. Mucocele (excludes benign, asymptomatic mucus retention cysts),

5. Recurrent sinusitis with significant associated comorbid conditions (some examples include immune system disorders, and congenital or acquired ciliary dyskinesia),

6. Recurrent sinusitis which exacerbates significant comorbid conditions (including but not limited to asthma, recurrent bronchitis or pneumonia, diabetes),

7. Multidrug resistant organisms identified by culture,

8. Sinonasal benign or malignant tumor (including inverted papilloma),

9. Cerebrospinal fluid leak (CSF leak),

10. Dacryocystorhinostomy (DCR) for disorders of the lacrimal system,

11. Orbital or optic nerve decompression,

12. Repair of choanal atresia.

13. Silent Sinus Syndrome

14. Antrchoanal Polyps

15. Fungal ball or mycetoma

16. Fungal Sinusitis

The use of a mometasone furoate sinus implant (e.g., Propel®, Propel Mini®, and Propel Contour®) is considered medically necessary following functional endoscopic sinus surgery (FESS) or other sinus procedure when the following criteria are met:

1. Individual is ≥ 18 years of age; AND
2. Ethmoid or frontal sinus surgery is planned; AND
3. Individual has one or more of the following conditions:
   a. Polypoid disease
   b. Failed prior surgery and/or restenosis
   c. Absolute or relative contraindication to systemic steroids
4. The functional endoscopic sinus surgery (FESS) or other primary sinus procedure is considered medically necessary.

When surgical treatment of sinus disease is not covered

Functional endoscopic sinus surgery for sinus disease is considered not medically necessary for the treatment of sinusitis or polyposis when the criteria above are not met.

The use of a mometasone furoate sinus implant (Propel®) is considered not medically necessary when the criteria above are not met.

A mometasone furoate sinus implant (Propel®) is contraindicated when:

- individual has suspected or confirmed intolerance to mometasone furoate.
- individual has a known hypersensitivity to lactide, glycolide, or caprolactone copolymers.
Surgical Treatment of Sinus Disease

The use of a mometasone furoate sinus implant (Sinuva™) in the treatment of sinonasal polyposis is considered investigational.

Policy Guidelines

Optimal medical treatment

Functional endoscopic sinus surgery (FESS) should be reserved for use in individuals in whom optimal medical treatment has failed. The majority of individuals with sinusitis do not require surgery. Their sinus symptoms can usually be successfully treated medically, including antibiotic therapy and other medications, treatment of allergy, and environmental control.

Optimal medical treatment consists of the following:

1. Oral antibiotics of 2 weeks duration for individuals with chronic rhinosinusitis if evidence of bacterial infection on endoscopy
2. Oral antibiotics with multiple 1-2 week courses for individuals with recurrent acute rhinosinusitis
3. Intranasal steroids for at least one month
4. Systemic steroids (at the discretion of the physician)
5. Saline irrigations (optional)
6. Topical and/or systemic decongestants (optional, if not contraindicated)
7. Treatment of concomitant allergic rhinitis, including avoidance measures, pharmacotherapy, and/or immunotherapy (at the discretion of the physician)

Note: Imaging studies should be generally obtained after appropriate medical therapy. Based on the clinical situation (i.e., concern for sinus complications or neoplasm), early or emergent imaging may be required to confirm a diagnosis. Early imaging is also indicated in recurrent acute rhinosinusitis.

Endoscopic Sinus Surgery in the Pediatric Population

Prior to performing endoscopic sinus surgery in the pediatric population, the following must be documented.

1. A comprehensive history
   a. Failure of medical management for chronic rhinosinusitis or recurrent acute rhinosinusitis, possibly in addition to other disorders, including, but not limited to:
      * Allergy
      * Day care exposure
      * Gastroesophageal reflux contributing to rhinosinusitis
      * Adenoiditis and/or obstructive adenoid hypertrophy
      * Cystic fibrosis
      * Immune deficiency disorders
      * Ciliary dysfunction/dyskinesia
      * Progressively worsening asthma with opaque sinus(es)
      * Nasal polyposis with airway obstruction and/or sinusitis
      * Suspected neoplasm (e.g., juvenile nasopharyngeal angiofibroma)
      * Adenoidectomy should be strongly considered a minimum of three months prior to performing pediatric sinus surgery for any of the above indications
      * Intracranial complications
      * Cavernous sinus thrombosis
      * Mucoceles and mucopyoceles
      * Subperiosteal or orbital abscess/peri orbital cellulitis
      * Traumatic injury to optic canal (decompression)
      * Dacryocystitis from rhinosinusitis
      * Meningocephalocele
Surgical Treatment of Sinus Disease

- Cerebrospinal fluid leaks
- Tumors of the nasal cavity, paranasal sinuses, orbit or skull base
- Recurrent acute rhinosinusitis (RARS)

2. Physical examination, including complete anterior and posterior nasal examination (rhinoscopy after mucosal decongestion) as possible for individual’s age

3. Other tests, including for surgical planning, a coronal CT scan following medical therapy is required. A complete axial CT scan is recommended in cases with complex disease. MRI, culture and sensitivity, and allergy testing are optional.

4. Optimal medical therapy, including
   a. Evaluation and management for all medical conditions listed above
   b. Treatment of rhinitis medicamentosa, when present
   c. Parental education of environmental factors including allergens, irritants, or secondhand tobacco smoke
   d. Antibiotic therapy when indicated
   e. Appropriate topical and/or systemic steroids when indicated

Steroid-Eluting Sinus Stents as an Adjunct to Endoscopic Sinus Surgery

Drug-eluting sinus implants have been used post-FESS with the intent of maintaining patency of the sinuses and delivering local steroids. Two RCTs have compared the Propel™ device with steroids to the same device without steroids, and reported that the steroid-eluting device reduced postoperative inflammation, reduced the need for oral steroids, and reduced the need for postoperative reinterventions. These trials evaluate the benefit of local steroid delivery in addition to standard care. The improvements reported in these trials reflect the impact of local steroid delivery, which was withheld in the control arm.

Steroid-Eluting Sinus Implant (Sinuva) for Recurrent Polyposis

Han et al (2014) reported on results from RESOLVE, a sham-controlled randomized trial evaluating the use of office-based placement of a mometasone-eluting nasal implant (Sinuva) for patients with recurrent nasal polyposis after endoscopic sinus surgery. Eligible patients had chronic rhinosinusitis, had undergone prior bilateral total ethmoidectomy more than 3 months earlier, had endoscopically confirmed recurrent bilateral ethmoid sinus obstruction due to polyposis that was refractory to medical therapy, and were considered candidates for repeat surgery based on the judgment of the surgeon and patient. Patients and those who administered symptom questionnaires at follow-up visits were blinded to treatment group. The trial was powered to detect a between-group difference of at least a 0.6-point change in polyp grade from baseline, and at least a 1.0-point change in nasal obstruction/congestion score. One hundred subjects were randomized to treatment (n=53) or control (n=47). For endoscopically measured outcomes, at 90 days of follow-up, the treatment group had a greater reduction in polyp grade than the control group (-1.0 vs -0.1; p=0.016) and a greater reduction in percent ethmoid obstruction on a 100-mm VAS (-21.5 mm vs 1.3 mm; p=0.001), both respectively. For patient-reported outcomes, there were no significant differences in change in nasal obstruction/congestion scores between groups. Compared with controls, fewer treatment group patients required oral steroids for ethmoid obstruction (11% vs 26%) and fewer treatment group patients were indicated for sinus surgery at 3 months based on established criteria (47% vs 77%), although statistical comparisons were not reported.

Forwith et al (2016) reported six month follow-up results from the RESOLVE trial. Treated patients experienced improvement in Nasal Obstruction Symptom Evaluation (NOSE) score (p=0.02) and greater than 2 fold improvement in mean nasal obstruction/congestion score p=0.12). Endoscopically, treated patients showed reduction in ethmoid sinus obstruction (p=0.01) and a two-fold improvement in bilateral polyp grade (p=0.099).
Surgical Treatment of Sinus Disease

The RESOLVE trial had a high risk of bias due to unblinded outcome assessment. Although avoidance of repeat endoscopic sinus surgery and oral steroids may be relevant outcomes for this indication, it would be more important if decisions about repeat surgery or other treatments were standardized and, in the trial setting, if decisions were prespecified or made by a clinician blinded to treatment group.

Kern et al (2018) reported on results from RESOLVE II, a sham-controlled, double-blind, randomized trial evaluating mometasone-eluting sinus implants in patients with recurrent polyposis after sinus surgery. Three hundred patients with refractory chronic rhinosinusitis with nasal polyps who were candidates for repeat surgery, were randomized to in-office bilateral placement of implants or sham procedure. Treated patients experienced reductions in both nasal obstruction/congestion score (p=0.007) and bilateral polyp grade (p=0.007), compared to controls. There was a 61% reduction in the need for repeat sinus surgery at 90 days in the treatment group versus 37% reduction among sham patients. Limitations to the study included absence of a defined medical regimen prior to enrollment, and the clinical investigators who performed the endoscopic grading and assessment for indication for repeat surgery at day 90 were not blinded to treatment assignment. Additional trials with longer follow-up beyond 90 days are needed to assess duration of the effect of the stent on recurrent nasal polyps.

Billing/Coding/Physician Documentation Information

This policy may apply to the following codes. Inclusion of a code in this section does not guarantee that it will be reimbursed. For further information on reimbursement guidelines, please see Administrative Policies on the Blue Cross Blue Shield of North Carolina web site at www.bcbsnc.com. They are listed in the Category Search on the Medical Policy search page.

Applicable codes: 31237, 31241, 31253, 31254, 31255, 31256, 31257, 31259, 31267, 31276, 31287, 31288, 31299, J7402, S1091, S2342

BCBSNC may request medical records for determination of medical necessity. When medical records are requested, letters of support and/or explanation are often useful, but are not sufficient documentation unless all specific information needed to make a medical necessity determination is included.

Scientific Background and Reference Sources


National Institute of Allergy and Infectious Diseases. Sinus Infection (Sinusitis). Available at: http://www.niaid.nih.gov/topics/sinusitis/Pages/Index.aspx

Medical Director review 2/2010

Medical Director review 7/2010


Medical Director review 6/2012
Surgical Treatment of Sinus Disease


Surgical Treatment of Sinus Disease


Medical Director review 5/2018


Specialty Matched Consultant Advisory Panel - 8/2018


Medical Director review 11/2018


Medical Director review 7/2020


Medical Director review -8/2023


Policy Implementation/Update Information
Surgical Treatment of Sinus Disease

3/30/2010 New policy issued. BCBSNC will cover functional endoscopic sinus surgery (FESS) when determined to be medically necessary because the medical criteria and guidelines outlined in the policy are met. Notification given 3/30/10 for effective date 7/1/10. (adn)

7/6/2010 Specialty Matched Consultant Advisory Panel review 5/24/10. No change to policy statement or coverage criteria. (adn)

7/20/2010 Minor changes in Description section. In the When FESS is covered section: Revised Item 1.c. to read “For chronic rhinosinusitis, documentation of coronal CT and/or nasal endoscopy following optimal medical therapy showing persistent sinus pathology.” Added item 1.d. which reads “For recurrent acute rhinosinusitis, coronal CT and nasal endoscopy may be normal after treatment. However, CT and/or nasal endoscopy during acute rhinosinusitis should document sinus pathology amenable to surgical treatment.” Revised Item 2 to read “Multiple or recurrent polyps with airway obstruction and failure of optimal medical management (including assessment for allergy symptoms, and allergy evaluation if indicated) with persistent sinus disease on follow up CT scan and/or nasal endoscopy.” Revised Item 4 to read “Chronic anterior headache or facial pain…” Inserted new items 6, 7 and 8 which read “6) Recurrent sinusitis with significant associated comorbid conditions (some examples include immune system disorders, and congenital or acquired ciliary dyskinesia), 7) Recurrent sinusitis which exacerbates significant comorbid conditions (including but not limited to asthma, recurrent bronchitis or pneumonia, diabetes), and 8) Multidrug resistant organisms identified by culture. Revised newly numbered Item 9 to read “Sinonasal benign or malignant tumor (including inverted papilloma).” In the Policy Guidelines section, revised item 3.f. to read “antibiotic therapy consisting of three consecutive weeks of appropriate antibiotic drugs, OR multiple two to three week courses of appropriate antibiotic drugs during the symptomatic periods.” CPT Codes 31237 and 31240 deleted from the Billing/Coding section. (adn)

9/13/11 Specialty Matched Consultant Advisory Panel review 8/31/11. No change to policy statement or medical criteria. (adn)

6/29/12 Code S1090 added to policy. “The use of a Propel sinus implant may be considered medically necessary when the following criteria are met. 1. Implanted at the time of approved functional endoscopic sinus surgery, and 2. Implanted in the ethmoid sinus only” added to the When Covered section. “Use of the Propel sinus implant is considered not medically necessary if inserted at any surgical setting other than the FESS procedure, or for any sinus cavities other than the ethmoid…” added to the When Not Covered section. (sk)

7/24/12 Added information regarding implantable sinus stents/spacers for postoperative use following endoscopic sinus surgery to the Description section and to the Policy Guidelines section. Added “The use of implantable sinus stents/spacers for postoperative treatment following endoscopic sinus surgery is considered investigational. BCBSNC does not cover investigational services or supplies” to the When Not Covered section. References added. (sk)

11/13/12 Specialty Matched Consultant Advisory Panel review 8/15/12. Additional pediatric information added to Policy Guidelines. No change to policy statement. (sk)

11/12/13 Reference added. Existing references updated. Specialty Matched Consultant Advisory Panel review 8/21/13. Medical Director review. No change to policy statement. (sk)

2/25/14 Reference added. The word “spacer removed from its association with the word “stent” throughout the policy. No change to Policy intent. (sk)
Surgical Treatment of Sinus Disease

7/15/14  Description section updated to include general information on drug-eluting sinus implants and specific information on the Propel™ sinus implant. Medical necessity criteria for use of a mometasone furoate sinus implant added to When Covered section. Not medically necessary criteria for use of a mometasone furoate sinus implant added to When Not Covered section. Policy Guidelines updated. (sk)

11/25/14  References added and updated. Specialty Matched Consultant Advisory Panel review 10/2014. Medical Director review. Policy title changed from Functional Endoscopic Sinus Surgery (FESS) to Surgical Treatment of Sinus Disease. Conditions in which Balloon Ostial Dilation would be considered not medically necessary added to the When Not Covered Section. Definition of optimal medical treatment added. Statement added that “Balloon ostial dilation as a standalone procedure in an ambulatory setting must be performed by a board eligible/board certified otolaryngologist who has admitting privileges at a local hospital.” (sk)

10/1/15  Specialty Matched Consultant Advisory Panel review 8/26/15. (sk)

12/30/15  Codes 0406T and 0407T added to Billing/Coding section. (sk)

9/30/16  Specialty Matched Consultant Advisory Panel review 8/31/2016. Reference added and updated. (sk)


5/25/18  Medical Director review. The following statement added to the Billing/Coding section for additional clarity: “Balloon sinuplasty (codes 31295, 31296, 31297) performed in conjunction with functional endoscopic sinus surgery (FESS) within the same sinus cavity, is considered incidental to the major service and not eligible for separate reimbursement.” (sk)


10/01/19  Specialty Matched Consultant Advisory Panel review 9/20/2019. (sk)

6/30/20  New code C9122 added to Billing/Coding section. (sk)

7/14/20  Medical Director review. Criteria for balloon ostial dilation (BOD) moved to a separate medical policy. Silent sinus syndrome and antrochoanal polyps added to list of covered indication. (sk)

12/8/20  Specialty Matched Consultant Advisory Panel review 8/19/2020. Description section updated. Removed “Chronic headache or facial pain caused by a demonstrable anatomic or pathologic sinus disorder” from coverage criteria. Policy Guidelines updated. (sk)

Surgical Treatment of Sinus Disease

12/14/21  Specialty Matched Consultant Advisory Panel review 8/18/2021. Added Fungal ball or mycetoma to list of covered indications. (sk)

2/7/23  Specialty Matched Consultant Advisory Panel review 8/19/2022. (sk)


Medical policy is not an authorization, certification, explanation of benefits or a contract. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the group contract and subscriber certificate that is in effect at the time services are rendered. This document is solely provided for informational purposes only and is based on research of current medical literature and review of common medical practices in the treatment and diagnosis of disease. Medical practices and knowledge are constantly changing and BCBSNC reserves the right to review and revise its medical policies periodically.